Poliovirus vaccine inactivated - Takeda pharmaceutical company

Drug Profile

Poliovirus vaccine inactivated - Takeda pharmaceutical company

Alternative Names: Sabin-inactivated poliovirus vaccine - Takeda; Sabin-IPV; sIPV - Takeda

Latest Information Update: 12 May 2016

Price : $50

At a glance

  • Originator Takeda
  • Class Viral vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Poliomyelitis

Most Recent Events

  • 03 Apr 2017 Takeda plans a phase I/II trial for Poliomyelitis (Prevention, In infants, In children, In adolescents, In adults) (NCT03092791)
  • 08 May 2016 Early research in Poliomyelitis (Prevention) in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top